South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharma-q holdings (pty) ltd - injection - see ingredients - each 1 ml liquid contains epinephrine bitartrate 1,80 mg equivalent to epinephrine 1 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose; purified talc; maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Malta - English - Medicines Authority

hexal pharma gmbh stella-klein-low-weg 17, 1020 wein, austria - cilostazol - tablet - cilostazol 100 mg - antithrombotic agents

United Kingdom - English - myHealthbox

midas pharma gmbh - ceftriaxone sodium - powder for solution for injection - 0.596g - antibacterials for systemic use, third generation cephalosporins - it is indicated for the treatment of the following infections in adults and children including term neonates (from birth): • bacterial meningitis • community acquired pneumonia • hospital acquired pneumonia • acute otitis media • intra-abdominal infections • complicated urinary tract infections (including pyelonephritis) • infections of bones and joints • complicated skin and soft tissue infections • gonorrhoea • syphilis • bacterial endocarditis

United Kingdom - English - myHealthbox

midas pharma gmbh - ceftriaxone sodium - powder for solution for infusion - 2.38g - antibacterials for systemic use, third generation cephalosporins - it is indicated for the treatment of the following infections in adults and children including term neonates (from birth): • bacterial meningitis • community acquired pneumonia • hospital acquired pneumonia • acute otitis media • intra-abdominal infections • complicated urinary tract infections (including pyelonephritis) • infections of bones and joints • complicated skin and soft tissue infections • gonorrhoea • syphilis • bacterial endocarditis

United Kingdom - English - myHealthbox

mip pharma gmbh - ceftazidime - powder for solution for injection/infusion - 1g - antibacterials for systemic use. third-generation cephalosporins - it is indicated for the treatment of the infections listed below in adults and children including neonates (from birth). - nosocomial pneumonia - broncho-pulmonary infections in cystic fibrosis - bacterial meningitis - chronic suppurative otitis media - malignant otitis externa - complicated urinary tract infections - complicated skin and soft tissue infections - complicated intra-abdominal infections - bone and joint infections - peritonitis associated with dialysis in patients on capd

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:* patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.